Skip to main content
Premium Trial:

Request an Annual Quote

Scottsdale Healthcare Becomes Clinical Research Center for TGen

NEW YORK, Oct. 20 (GenomeWeb News) - Scottsdale Healthcare today said that it will become a primary clinical research site for the Translational Genomics Research Institute.


The TGen Clinical Research Services, set to open Oct. 24, will include a Genomics Medicine and IndividualTherapyCenterand a PancreaticCancerCenter. It will be located in the VirginiaG.PiperCancerCenterat Scottsdale Healthcare.


TGen said that additional clinical research programs focused on other cancer types are planned in the near future.


Daniel Von Hoff, TGen's senior investigator and director of the Translational Drug Development Division, will serve as medical research leader of TCRS. As the new program grows it is expected to move into a larger space in the Cancer Center's adjoining Research Pavilion, TGen said.


Von Hoff said the alliance "will allow molecular and genomic discoveries made by TGen and others around the world to reach the patient bedside as quickly as possible."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.